The global guacamole market is set to rise at a CAGR of around 7% through 2031, to be valued at US$ 2.3 Bn, with demand for organic guacamole rising faster across geographies. Rising awareness about environmentally stable cultivation practices and the need for natural and nutritious foods are steadily creating demand for organic-labeled foods. Guacamole is no exception to this, even though the market share is less as compared to conventional guacamole. Still, y-o-y growth indicates optimistic growth for organic guacamole. Guacamole can be utilized as a dip for chips, meat, fish, vegetables, and fruits, and can also be utilized as a salad dressing. The versatility that guacamole has to offer has enabled manufacturers to endorse their products as an easy-to-go food. As such, with growing demand for organically labeled foods, organic guacamole is anticipated to witness a value CAGR of more than 8% over the next ten years.
To remain ‘ahead’ of your competitors, request for a samples@https://www.persistencemarketresearch.com/samples/32514
Key Takeaways from Market Study
- The guacamole market in India and China is anticipated to grow at CAGRs of 9.3% and 8.6%, respectively, through 2031.
- By flavor, unflavored/plain guacamole will witness a prominent market value share up to 70% by 2031. This is due to its low cost when compared to flavored guacamole.
- North America and Latin America hold more than half the share of the global market, mainly on back of high consumption of avocado-based products in these regions.
- In Asia Pacific, manufacturers are increasingly cresting new and regional dedicated flavors for guacamole due to the relevance of avocado as an aspirational lifestyle and increasing living standards in countries such as India, China, Indonesia, and Thailand.
- Guacamole demand is expected to surge at a value CAGR of more than 6% in Europe and the U.S. over the forecast period.
- Spain, Germany, France, Russia, and BENELUX hold significant shares for guacamole in Europe.
- COVID-19 has had a low impact on the progress of the guacamole industry. Disruptions of supply chains were witnessed, but the market is expected to recover in the short-term.
To connect with our sales representative@[email protected]
Competitive Landscape
Guacamole manufacturers are focusing on increasing their market share by investing in research & development to develop new flavors to suit consumers’ changing taste preferences and also acquiring trending labels. Manufacturers are constantly making efforts to increase sales across various regions.
- In July 2020, Westfalia Fruit Group launched two rootstocks after testing avocados in different infection pressure conditions, to sustain the fruit, which can further be utilized for making guacamole.
- In 2020, Verfruco Foods Inc. invested in research &development of technology for cleaning and simplifying processing of avocados as a raw material for making guacamole.
- Landec Corporation, which owns major guacamole brands Ortega and Cabo Fresh, is working on developing more products to keep pace with the demand for plant-based products.
For in-depth competitive analysis, buy now@https://www.persistencemarketresearch.com/checkout/32514
Read More Trending “PMR Exclusive Article”
- Global Market Study on Algal Oil: https://www.persistencemarketresearch.com/market-research/algal-oil-market.asp
- Global Market Study on Heart Health Supplements: https://www.persistencemarketresearch.com/market-research/heart-health-supplements-market.asp
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
The global Guacamole Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the guacamole market include Calavo Growers Inc., Salud Food Group Europe B.V., Frontier Natural Products Co-Op, Avo-King International Inc., Curation Foods Inc., Conagra Brands Inc., B Foods Inc., MegaMex Foods LLC, Landec Corporation, and Sabra Dipping Company LLC.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Guacamole Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/guacamole-market/download-sampleMarket DynamicsThe key factors influencing the popularity and consumption of guacamole worldwide is the globalization of food systems in developing countries,greater availability and diversity of food, strengthening procurement and distribution systems and the food trade environment, gradual shift in food culture, changes in dietary consumption patterns and nutritional status, and individuals opting healthier lifestyles by consuming wholesome foods.
Guacamole is gaining popularity as a dip, spread, or salad at the international level due to its mouth-watering taste and health benefits.
Guacamoles are high in potassium and good sources of vitamin C and E and antioxidants.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
